Medical directoryActive ingredient
Semaglutide
A once-weekly GLP-1 receptor agonist (also available as a once-daily oral formulation). Licensed in Spain under different brand names and for different indications: type 2 diabetes and weight management are separate indications with separate presentations.
Content reviewed by Dr. David Céspedes
Medical guides
Insulin resistance: symptoms, how it is diagnosed and how to reverse it
ReadMounjaro reviews: what the trials show and what patients report
ReadRybelsus price in Spain: cost per dose (3, 7 and 14 mg) and per month
ReadOzempic price in Spain: how much it costs per pen and per month in 2026
ReadOrforglipron (Foundayo), approved by the FDA: the first GLP-1 pill that can be taken without food or water restrictions
ReadSurvodutide: what it is and where it currently stands
ReadWeight regain after stopping treatment: why it happens and how it is managed
ReadMetabolic fatty liver disease: what it is, why it happens and what can be done
ReadOrforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain
ReadRetatrutide: what its phase 3 trial found, and why you can't get hold of it
ReadCagriSema: what it is, what the REDEFINE trials found and why it disappointed
ReadBuying Ozempic and Mounjaro in Spain: how to get them legally and safely
ReadOzempic and Mounjaro side effects: what to expect and how to manage them
ReadGLP-1: what it is, how it works and why it is transforming obesity treatment
ReadMounjaro vs Ozempic: clinical differences, effectiveness and which one suits you
ReadOzempic in Spain: what it is, how it works and who can take it
Read
Keep reading
This entry is for information. Your case requires an individual medical assessment.